Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.
In this week's installment, Merck (NYSE:MRK) gave us an update on its Alzheimer's program last week, and now, Eli Lilly (NYSE:LLY) has given an update on its Alzheimer's drug solanezumab. The company plans to conduct further phase 3 trials for patients with a milder form of the disease, despite failures with the drug in other phase 3 trials, as the data suggests there may be some benefit for those patients.
Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Elan and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.